323 related articles for article (PubMed ID: 35807171)
21. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
Jia X; Liu J; Mehta A; Ballantyne CM; Virani SS
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1269-1279. PubMed ID: 32997212
[TBL] [Abstract][Full Text] [Related]
22. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries.
Nishikido T; Ray KK
Front Cardiovasc Med; 2018; 5():199. PubMed ID: 30761308
[TBL] [Abstract][Full Text] [Related]
23. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
[TBL] [Abstract][Full Text] [Related]
25. Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.
Banaszewska A; Piechota M; Plewa R
Cell Mol Biol Lett; 2012 Jun; 17(2):228-39. PubMed ID: 22311433
[TBL] [Abstract][Full Text] [Related]
26. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
27. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
28. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
Mahmood T; Shapiro MD
Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
[TBL] [Abstract][Full Text] [Related]
29. Liver as a target for oligonucleotide therapeutics.
Sehgal A; Vaishnaw A; Fitzgerald K
J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
[TBL] [Abstract][Full Text] [Related]
30. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
31. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.
Rached F; Santos RD
Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216
[TBL] [Abstract][Full Text] [Related]
32. [Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations].
Klose G; Gouni-Berthold I; März W
Inn Med (Heidelb); 2023 Sep; 64(9):895-906. PubMed ID: 37280381
[TBL] [Abstract][Full Text] [Related]
33. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
34. Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing.
Wang X; Musunuru K
JACC Basic Transl Sci; 2019 Oct; 4(6):755-762. PubMed ID: 31709322
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.
Kotani K; Banach M
J Thorac Dis; 2017 Jan; 9(1):E78-E82. PubMed ID: 28203441
[TBL] [Abstract][Full Text] [Related]
36. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.
Merćep I; Friščić N; Strikić D; Reiner Ž
Cardiovasc Ther; 2022; 2022():8129513. PubMed ID: 35237348
[TBL] [Abstract][Full Text] [Related]
37. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
Romagnuolo R; Scipione CA; Boffa MB; Marcovina SM; Seidah NG; Koschinsky ML
J Biol Chem; 2015 May; 290(18):11649-62. PubMed ID: 25778403
[TBL] [Abstract][Full Text] [Related]
38. Inclisiran in lipid management: A Literature overview and future perspectives.
Scicchitano P; Milo M; Mallamaci R; De Palo M; Caldarola P; Massari F; Gabrielli D; Colivicchi F; Ciccone MM
Biomed Pharmacother; 2021 Nov; 143():112227. PubMed ID: 34563953
[TBL] [Abstract][Full Text] [Related]
39. Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels-Potent Clinical Implications.
Koutsogianni AD; Liamis G; Liberopoulos E; Adamidis PS; Florentin M
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242533
[TBL] [Abstract][Full Text] [Related]
40. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
Wang Y; Liu ZP
Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
